|
|
|
 The IMF is pleased to bring you CITINGS - Novel Therapies, now published monthly, featuring the most up-to-date information on research advances and new therapies for the treatment for multiple myeloma. CITINGS - Novel Therapies provides physicians and other health care professionals with references and Internet links to the most current U.S. and international journal articles, abstracts, and white papers. Each issue presents articles related to new drugs, either as the focus of the study or as part of the discussion of myeloma treatment.
|
|
|
|
![]()
|
This special edition of CITINGS highlights presentations that will be made at the 53rd annual meeting of the American Society of Hematology (ASH), held December 10–13, 2011. |
|
|
|
![]()
|
This special edition corresponds with the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). In this CITINGS, we have highlighted selected thalidomide and Revlimid data presentations from the ASCO meeting. We also provide references to the latest published journal articles on both
thalidomide and Revlimid from the second quarter of this year. |
|
|
|
![]()
|
This special edition corresponds with the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). In this CITINGS, we have highlighted selected VELCADE data presentations from the ASCO meeting. We also provide references to the latest published journal articles on VELCADE from the second quarter of this year. |
|
|
|
![]()
|
This special edition corresponds with the 43rd annual meeting of American Society of Clinical Oncology (ASCO). In this CITINGS, we have highlighted selected VELCADE data presentations from the ASCO meeting. We also provide references to the latest published journal articles on VELCADE from the second quarter of this year. |
|
|
|
![]()
|
This special edition corresponds with the 43rd annual meeting of American Society of Clinical Oncology (ASCO). In this CITINGS, we have highlighted selected thalidomide and Revlimid data presentations from the ASCO meeting. We also provide references to the latest published journal articles on both thalidomide and Revlimid from the second quarter of this year. |
|
|
|
![]()
|
The International Myeloma Foundation (IMF) is pleased to present our first edition of CITINGS for 2007. In this issue you will find references to the latest published journal articles on both thalidomide and Revlimid from the first quarter ofthis year. |
|
|
|
![]()
|
This issue focuses on VELCADE (bortezomib), the first of a new class of drugs called proteasome inhibitors. In this issue, we provide a list of eferences to the latest published studies on bortezomib from both national and international medical journals and publications. |
|
|
|
![]()
|
This special edition corresponds with the48th American Society of Hematology (ASH) annual meeting. In this CITINGS, we havehighlighted selected thalidomide and Revlimid data presentations from the ASH meeting. We also provide references to the latest published journal articles on both thalidomide and Revlimid from the fourth quarter of this year. |
|
|
|
![]()
|
This issue focuses on VELCADE (bortezomib), the first of a new class of drugs called proteasome inhibitors. In this issue, we provide a list of selected bortezomib data being presented at the annual American Society of Hematology (ASH) Meeting to be held December 8–12, 2006.
|
|
|
|
![]()
|
The IMF is pleased to present our third edition of CITINGS for 2006. This quarterly publication features citations to the most up-to-date studies on myeloma treatment. In this issue, we focus on thalidomide and Revlimid for the treatment of multiple myeloma. Inside you will find references to the latest published journal articles on both thalidomide and Revlimid from the third quarter of this year. |
|
|
|
![]()
|
This issue focuses on VELCADE (bortezomib), the first of a new class of drugs called proteasome inhibitors. In this issue, we provide a list of selected bortezomib data being presented at the annual American Society of Clinical Oncology (ASCO) meeting to be held June 2-6, 2006. As always, readers will also find a comprehensive list of references to the latest published studies on bortezomib from both national and international medical journals and publications. |
|
|
|
![]()
|
The IMF presents this special edition of CITINGS, our premiere publication featuring the most up-to-date information on myeloma treatment, focused on thalidomide and Revlimid®. This special edition corresponds with the annual meeting of the American Society of Clinical Oncology (ASCO) meeting to be held June 2-6, 2006. In this CITINGS, we have highlighted selected thalidomide and Revlimid data presentations from the ASCO meeting. We also provide references to the latest published journal articles on both thalidomide and Revlimid from the first quarter of this year. |
|
|
|
![]()
|
We are pleased to present our first edition of CITINGS for 2006. This quarterly publication features citations to the most up-to-date studies on myeloma treatment. In this issue, we focus on thalidomide and Revlimid® for the treatment of multiple myeloma. Inside you will find references to the latest published journal articles on both thalidomide and Revlimid from the first quarter of this year. |
|
|
|
![]()
|
In this issue we are continuing our series focusing specifically on publications referring to thalidomide and its analogues. In addition to our usual summary of publications found in scientific journals, we have added to this issue summaries of all the major papers presented at the three large hematology meetings that have taken place so far in 2005. In it you will find summaries from:
1. the 10th International Myeloma Workshop held this year in Sydney, Australia from April 10 - 14,
2. the American Society of Clinical Oncology (ASCO) meeting held in Orlando from May 14 - 17 and,
3. the 10th Congress of the European Hematology Association held in Stockholm, Sweden, from June 2 - 5. |
|
|
|
![]()
|
The IMF is pleased to present our first VELCADE® (bortezomib)-focused edition of CITINGS for 2005, a relatively recent publication featuring the most up-to-date information on new therapies for multiple myeloma. VELCADE is the first of a new class of drugs called proteasome inhibitors. Because it is a new type of drug, VELCADE represents a new treatment option for patients who have relapsed on other standard therapies. This issue of CITINGS has been prepared by the IMF to correspond with the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. In this issue, readers will find three key resources related to VELCADE: 1) a list of selected bortezomib data presented at the ASCO meeting, along with dates and times of each presentation, 2) a list of selected bortezomib-related studies presented at the 10th International MyelomaWorkshop in Sydney, Australia from April 10th- 14th 2005, and 3) references to the latest published studies on bortezomib. |
|
|
|
![]()
|
The IMF is pleased to present our third issue of CITINGS for 2005. In this issue we are continuing our series focusing specifically on publications referring to Revlimid®. |
|
|
|
![]()
|
The IMF is pleased to present our second issue of CITINGS for 2005. In this issue we are continuing our series focusing specifically on publications referring to thalidomide. |
|
|
|
![]()
|
The IMF is pleased to present our first issue of CITINGS focused on kyphoplasty. Kyphoplasty is an innovative, minimally invasive surgical procedure for treating osteoporotic and cancer-related fractures in which an orthopedic balloon is inserted into the fractured bone in order to restore the bone to its pre-fracture height, and a cement-like material is then injected directly into the void created by the balloon. The procedure shows great promise in the treatment of painful osteoporotic or cancer-related vertebral compression fractures. |
|
|
|
![]()
|
This issue of CITINGS has been prepared by the IMF to correspond with the 46th American Society of Hematology (ASH) annual meeting in San Diego, California. In this issue, readers will find three key resources related to VELCADE: 1) a list of selected bortezomib data being presented at the ASH meeting, along with dates and times of each presentation, 2) a list of selected bortezomib-related studies presented at the European Hematology Association meeting, and 3) references to the latest published studies on bortezomib. |
|
|
|
![]()
|
In this edition, we continue our focus on thalidomide and Revlimid® (CC-5013) and highlight data presentations taking place at the American Society of Hematology (ASH) Annual Meeting. The IMF has selected key presentations and has listed the date and time of each to facilitate your scheduling needs. |
|
|
|
![]()
|
Our second issue continues our focus on thalidomide and Revlimid® for the treatment of myeloma. |
|
|
|
![]()
|
The IMF is pleased to introduce the first edition of CITINGS, a quarterly publication featuring the most up-to-date information on research advances and new therapies for the treatment for multiple myeloma. |
|
|
print
back to top